广州医药2024，Vol.55Issue(5)：489-493,499,6.DOI:10.3969/j.issn.1000-8535.2024.05.006
伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察
Efficacy of vonoprazan triple therapy for treatment of Helicobacter pylori
摘要
Abstract
Objective To explore the effect of vonoprazan triple therapy on Helicobacter pylori(Hp).Methods A total of 200 patients with Hp infection confirmed by 13C urea breath test from May-December 2022 were selected and divided into observation group and control group with 100 patients in each group.The observation group was treated with triple therapy of amoxicillin,furazolidone and vonoprazan,while the control group was treated with quadruple therapy of amoxicillin,furazolidone,esomeprazole magnesium and bismuth potassium citrate.The treatment course was 14 days.The 13C urea breath test was reviewed one month after treatment withdrawal to determine whether Hp eradication was successful,and the incidence of adverse drug reactions was observed.Results The eradication rate of Hp in the observation group was 96.97%,higher than 89.80%in the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusions The triple therapy of vonoprazan,amoxicillin and furazolidone has a very high eradication rate and good safety,which can be used as one of the treatment options for Hp.关键词
伏诺拉生/阿莫西林/呋喃唑酮/幽门螺杆菌/三联疗法Key words
vonoprazan/amoxicillin/furazoldone/Helicobacter pylori/triple therapy引用本文复制引用
李思荃,蔡祥胜,张伟铮,胡笑仪,孙宁,许研..伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察[J].广州医药,2024,55(5):489-493,499,6.基金项目
国家自然科学基金(81703333) （81703333）
广东省自然科学基金(2020A1515011326) （2020A1515011326）
